• Viatris posted Q1 2026 net earnings of $176.4 million, swinging from a loss a year earlier, while revenue rose 8% to $3.52 billion.
• Adjusted EBITDA climbed 14% to $1.05 billion, with adjusted EPS up 18% to $0.59.
• Free cash flow fell 29% to $348.4 million, while cash and cash equivalents increased to $1.8 billion.
• Scott A. Smith said results reflected “disciplined execution” and momentum in Greater China and North America, with Effexor SR launched in Japan for generalized anxiety disorder.
• 2026 guidance was reaffirmed, including revenue of $14.45 billion-$14.95 billion and free cash flow excluding transaction-related and restructuring-related costs of $1.95 billion-$2.35 billion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viatris Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605070659PR_NEWS_USPR_____NY52989) on May 07, 2026, and is solely responsible for the information contained therein.